Skip to content
buyNotable cluster of 4

N Scott Fine bought $213k of CYTH

Chief Executive Officer at Cyclo Therapeutics, Inc.. 299,402 shares at an average of $0.71, traded Apr 20, 2023, filed Apr 24, 2023.

Conviction score
62
Value
$213k
299,402 shares
Holdings after
444,402
+206% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $213k at market
    +12
  • Relative to holdings
    Holdings up 206%
    +10
  • Price context
    No price history yet
    0
  • Cluster
    4 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001437749-23-010877, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Apr 20, 2023POpen-market purchase
Common Stock
+299,402$0.71$213k444,402Apr 24, 2023
Apr 20, 2023POpen-market purchase
Warrant to Purchase Common Stockderivative
+299,402$0.13$37k299,402Apr 24, 2023

Related signals

Other insiders at Cyclo Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
42Moderate
CYTHbuy 4
Cyclo Therapeutics, Inc.
Francis Patrick Ostronic
director
$43k
59,881 shares
+37%
46Moderate
CYTHbuy 4
Cyclo Therapeutics, Inc.
Markus Sieger
director
$43k
59,881 shares
+59%
45Moderate
CYTHbuy 4
Cyclo Therapeutics, Inc.
Jeffrey Tate
Chief Operating Officer
$21k
29,941 shares
+93%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

N Scott Fine bought $213k of CYTH | InsiderTell